

Search

EN

Back

Hengrui Medicine Stock Gains 5.9% on Novel Cancer Drug Trial Approval

Back

Stock NewsThemesHengrui Medicine Stock Gains 5.9% on Novel Cancer Drug Trial Approval

Hengrui Medicine Stock Gains 5.9% on Novel Cancer Drug Trial Approval

Edgen Stock·Jan 05 2026, 15:05

Share to

Share to

Copy link

source:

[1] Hengrui Medicine (600276.SH): Received Drug Clinical Trial Approval Notice (https://www.aastocks.com/tc/stocks/analysis/c ...)

Recommend

Autolink Targets Next-Decade Vehicles With New PlatformJan 07 2026, 07:23 Louis Navellier Backs Nvidia, Palantir for 2026, Urges Exit from 'Junk Rally'Jan 07 2026, 07:12 Sanofi Targets Growth, Leveraging 40% Flu Vaccine Market ControlJan 07 2026, 07:09

Hot News

Top RetailersHome Depot Stock Rises 1.5% Despite Weak Earnings OutlookJan 07 2026, 07:28

Top RetailersBarron's Signals Consumer Shift to Goods, Tipping 11 StocksJan 07 2026, 07:27

AI ChipAMD Sets February 3 Date for Q4 2025 Earnings ReportJan 07 2026, 07:26

AI ChipAutolink Taps AMD to Build Next-Gen Intelligent Vehicle PlatformsJan 07 2026, 07:24